Pesorama Inc (PESO) News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...

Form 8-K - Current report

Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy

 SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy...

Form 8-K - Current report

Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures

ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Supernus Announces First Quarter 2024 Financial Results

Net sales of Qelbree® increased 75% to $45.1 million compared to first quarter 2023.Total revenues were $143.6...

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America PR...

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®The percentage...

Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...

Supernus Provides Regulatory Update for SPN-830

ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...